{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T23:10:23Z","timestamp":1769641823496,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Chinese National Science Foundation","doi-asserted-by":"crossref","award":["81773957"],"award-info":[{"award-number":["81773957"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science and Technology Major Projects for \"Major New Drugs Innovation and Development\"","award":["2018ZX09201001-001-001"],"award-info":[{"award-number":["2018ZX09201001-001-001"]}]},{"name":"Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), 111 Project","award":["B16046"],"award-info":[{"award-number":["B16046"]}]},{"name":"Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University","award":["SKLNMZZCX201820"],"award-info":[{"award-number":["SKLNMZZCX201820"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.biopha.2018.12.059","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:37:04Z","timestamp":1545179824000},"page":"99-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Administration of methyl palmitate prevents non-alcoholic steatohepatitis (NASH) by induction of PPAR-\u03b1"],"prefix":"10.1016","volume":"111","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Si","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhan","family":"Ullah Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Rong","family":"Qi-Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2018.12.059_bib0005","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ajg.2009.67","article-title":"NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study","volume":"104","author":"Adams","year":"2009","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.059_bib0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0028-1091978","article-title":"The epidemiology of nonalcoholic fatty liver disease: a global perspective","volume":"28","author":"Lazo","year":"2008","journal-title":"Semin. Liver Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.059_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"issue":"45","key":"10.1016\/j.biopha.2018.12.059_bib0020","doi-asserted-by":"crossref","first-page":"73309","DOI":"10.18632\/oncotarget.12325","article-title":"Keratin 18-deficiency results in steatohepatitis and liver tumors in old mice: a model of steatohepatitis-associated liver carcinogenesis","volume":"7","author":"Kira","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2018.12.059_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2007.02.009","article-title":"Epidemiology and natural history of NAFLD and NASH","volume":"11","author":"Ong","year":"2007","journal-title":"Clin. Liver Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.059_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/CS20030285","article-title":"Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients","volume":"106","author":"Videla","year":"2004","journal-title":"Clin. Sci. (Lond., Engl.: 1979)"},{"issue":"4","key":"10.1016\/j.biopha.2018.12.059_bib0035","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2018.12.059_bib0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2001-12927","article-title":"Etiopathogenesis of nonalcoholic steatohepatitis","volume":"21","author":"Chitturi","year":"2001","journal-title":"Semin. Liver Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.059_bib0045","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.taap.2011.04.016","article-title":"Anti-inflammatory and antifibrotic effects of methyl palmitate","volume":"254","author":"El-Demerdash","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.059_bib0050","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jbt.20150","article-title":"Methyl palmitate inhibits lipopolysaccharide-stimulated phagocytic activity of rat peritoneal macrophages","volume":"20","author":"Sarkar","year":"2006","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.059_bib0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1432-2277.2005.00185.x","article-title":"Benefit of Kupffer cell modulation with glycine versus Kupffer cell depletion after liver transplantation in the rat: effects on postischemic reperfusion injury, apoptotic cell death graft regeneration and survival","volume":"18","author":"Rentsch","year":"2005","journal-title":"Transp. Int."},{"issue":"2-3","key":"10.1016\/j.biopha.2018.12.059_bib0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tox.2005.02.001","article-title":"Methyl palmitate: inhibitor of phagocytosis in primary rat Kupffer cells","volume":"210","author":"Cai","year":"2005","journal-title":"Toxicology"},{"issue":"11","key":"10.1016\/j.biopha.2018.12.059_bib0065","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/BF02524285","article-title":"Identification of fatty acid methyl ester as naturally occurring transcriptional regulators of the members of the peroxisome proliferator-activated receptor family","volume":"31","author":"Schmidt","year":"1996","journal-title":"Lipids"},{"issue":"5","key":"10.1016\/j.biopha.2018.12.059_bib0070","doi-asserted-by":"crossref","first-page":"G1035","DOI":"10.1152\/ajpgi.00199.2004","article-title":"Obese and diabetic db\/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin","volume":"287","author":"Sahai","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"11","key":"10.1016\/j.biopha.2018.12.059_bib0075","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbalip.2014.08.015","article-title":"Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet","volume":"1841","author":"Tanaka","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2018.12.059_bib0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2003.09.020","article-title":"The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance","volume":"40","author":"Rinella","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2018.12.059_bib0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jhep.2008.03.026","article-title":"MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes","volume":"49","author":"Larter","year":"2008","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2018.12.059_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155163","article-title":"Susceptibility of different mouse wild type strains to develop diet-induced NAFLD\/AFLD-Associated liver disease","volume":"11","author":"Fengler","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2018.12.059_bib0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2003.50307","article-title":"Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice","volume":"38","author":"Ip","year":"2003","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.biopha.2018.12.059_bib0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0378-4274(96)03639-9","article-title":"Reduction of the concentrations of prostaglandins E2 and F2alpha, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate","volume":"85","author":"Leung","year":"1996","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.biopha.2018.12.059_bib0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0065-2571(93)90017-8","article-title":"Peroxisomal leukotriene degradation: biochemical and clinical implications","volume":"33","author":"Jedlitschky","year":"1993","journal-title":"Adv. Enzyme Regul."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.059_bib0110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0022-2275(20)33350-2","article-title":"In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARalpha-deficient mice","volume":"40","author":"Gueraud","year":"1999","journal-title":"J. Lipid Res."},{"issue":"45","key":"10.1016\/j.biopha.2018.12.059_bib0115","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.059_bib0120","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/hep.510270601","article-title":"Hepatic steatosis: innocent bystander or guilty party?","volume":"27","author":"Day","year":"1998","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"8","key":"10.1016\/j.biopha.2018.12.059_bib0125","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI8814","article-title":"CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis","volume":"105","author":"Leclercq","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.biopha.2018.12.059_bib0130","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0168-8278(03)00376-3","article-title":"Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis","volume":"39","author":"George","year":"2003","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.059_bib0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1006\/bbrc.2000.2967","article-title":"4-hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression","volume":"273","author":"Kumagai","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.059_bib0140","first-page":"137","article-title":"Chemotactic activity of hydroxyalkenals on rat neutrophils","volume":"7","author":"Curzio","year":"1985","journal-title":"Int. J. Tissue React."},{"issue":"5","key":"10.1016\/j.biopha.2018.12.059_bib0145","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1172\/JCI118304","article-title":"Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression","volume":"96","author":"Lee","year":"1995","journal-title":"J. Clin. Invest."},{"issue":"52","key":"10.1016\/j.biopha.2018.12.059_bib0150","doi-asserted-by":"crossref","first-page":"50237","DOI":"10.1074\/jbc.M201208200","article-title":"Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production","volume":"277","author":"Xu","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.biopha.2018.12.059_bib0155","doi-asserted-by":"crossref","first-page":"16154","DOI":"10.1074\/jbc.M400346200","article-title":"Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate","volume":"279","author":"Gervois","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.biopha.2018.12.059_bib0160","doi-asserted-by":"crossref","first-page":"e6796","DOI":"10.1371\/journal.pone.0006796","article-title":"Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human","volume":"4","author":"Rakhshandehroo","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2018.12.059_bib0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/1574887109666141216102458","article-title":"Role of adipokines and cytokines in non-alcoholic fatty liver disease","volume":"9","author":"Abenavoli","year":"2014","journal-title":"Rev. Recent Clin. Trials"},{"issue":"2","key":"10.1016\/j.biopha.2018.12.059_bib0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1189\/jlb.0602325","article-title":"The many faces of macrophage activation","volume":"73","author":"Mosser","year":"2003","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.059_bib0175","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.biopha.2018.12.059_bib0180","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor _ negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-_B and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"47","key":"10.1016\/j.biopha.2018.12.059_bib0185","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M004045200","article-title":"Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators","volume":"275","author":"Delerive","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.059_bib0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.059_bib0195","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","article-title":"TGF-beta in progression of liver disease","volume":"347","author":"Dooley","year":"2012","journal-title":"Cell Tissue Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.059_bib0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2018.12.059_bib0205","doi-asserted-by":"crossref","first-page":"d793","DOI":"10.2741\/gressner","article-title":"Roles of TGF-beta in hepatic fibrosis","volume":"7","author":"Gressner","year":"2002","journal-title":"Front. Biosci."},{"key":"10.1016\/j.biopha.2018.12.059_bib0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/003655298750026561","article-title":"Experimental and human liver fibrogenesis","volume":"228","author":"Kovalszky","year":"1998","journal-title":"Scand. J. Gastroenterol. Suppl."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218365442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218365442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:29:59Z","timestamp":1760095799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218365442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":42,"alternative-id":["S0753332218365442"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.059","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Administration of methyl palmitate prevents non-alcoholic steatohepatitis (NASH) by induction of PPAR-\u03b1","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}